Australia's most trusted
source of pharma news
Posted 1 December 2021 AM
BMS is set to lose around $15 million from the value of leukemia drug Sprycel thanks to a 25 per cent price cut as it moves from F1 to F2 on the PBS today (Wednesday).
The patent expiry that brought on the cut also opens the way to competition that will further devalue the drug for its originating sponsor.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.